FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Clinical Trials Arena on MSN
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient deathIntellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
Intellia Therapeutics Inc. shares dropped after the company said a patient died after suffering liver damage in a clinical trial for the company’s gene-editing treatment. The patient, who was in his ...
The FDA has officially limited the label of Sarepta Therapeutics’ Elevidys, putting an end to a whirlwind few months that saw the abrupt departure—and reinstatement—of top agency official Vinay Prasad ...
Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who experienced a liver-related adverse event in a Phase 3 trial for its nex-z ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback